INVESTOR RELATIONS

News

Date Title and Summary Additional Formats
Toggle Summary ImmunityBio, NantKwest Announce First Patient Dosed in Phase 1 Clinical Trial of Second-Generation COVID-19 Vaccine Candidate Delivering Both Spike and Nucleocapsid of SARS-CoV-2
First patient receives ImmunityBio’s second-generation hAd5 COVID vaccine, delivering both outer S (spike) protein and inner N (nucleocapsid) leading to potential long-term T cell and antibody immunity to the SARS-CoV-2 virus CULVER CITY, Calif. & EL SEGUNDO, Calif. --(BUSINESS WIRE)--Oct.
View HTML
Toggle Summary FDA Authorizes Phase 1 Trial of ImmunityBio’s Novel COVID-19 Vaccine Candidate hAd5; Dual Construct is Designed to Drive Both T Cell and Antibody Immunity
First human adenovirus (hAd5) vector vaccine candidate to deliver both outer spike (S) and inner nucleocapsid (N) antigens from SARS-CoV-2, offering potential long-term T cell and antibody immunity to the SARS-CoV-2 virus Second-generation adenoviral vector platform designed to generate immune
View HTML
Toggle Summary NantKwest, ImmunityBio Add Third-Line Cohort to Phase 2 Pancreatic Cancer Trial; Opens Study to Patients Who Have Failed All Approved Standards of Care
 Third cohort added to independently evaluate the efficacy of NantKwest’s PD-L1 t-haNK natural killer cells plus ImmunityBio’s IL-15 superagonist Anktiva™ (N-803) in third-line or greater therapy for patients with locally advanced or metastatic pancreatic cancer.
View HTML
Toggle Summary NantKwest to Present at the 7th Annual Jefferies Cell Therapy Summit
EL SEGUNDO, Calif. --(BUSINESS WIRE)--Sep. 21, 2020-- NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Patrick Soon-Shiong , M.D., Chairman and CEO, will present at the virtual Jefferies Cell Therapy Summit on Tuesday, October 6,
View HTML
Toggle Summary Brink Biologics Announces License Agreement with Global Healthcare Company Fresenius Kabi SwissBioSim GmbH
SAN DIEGO --(BUSINESS WIRE)--Sep. 10, 2020-- Brink Biologics, Inc. (“Brink”), a NantKwest, Inc. (NASDAQ: NK) affiliate and exclusively-licensed distributor of NantKwest’s proprietary off-the-shelf NK-92® natural killer cells in certain fields, announces the licensing of its next-generation natural
View HTML
Toggle Summary NantKwest and ImmunityBio Sign Collaboration Agreement for Joint Development, Manufacturing, Marketing, and Commercialization of COVID-19 Vaccine and Related Therapeutics
Both companies agree to share equally in costs relating to COVID-19 therapeutics and vaccine candidates globally; global net profits to be shared 60%/40% in favor of the company contributing the product EL SEGUNDO, Calif. & CULVER CITY, Calif. --(BUSINESS WIRE)--Aug. 24, 2020-- NantKwest, Inc.
View HTML
Toggle Summary Cord Blood Registry (CBR®) by Generate Life Sciences Partners With NantKwest to Develop COVID-19 Treatment
CBR to Provide Umbilical Cord-Derived Cellular Material to NantKwest for additional COVID-19 Clinical Trials Utilizing MSC Therapy Los Angeles, Calif., and El Segundo, Calif., August 10, 2020 – CBR® by Generate Life Sciences, the world’s largest private newborn stem cell bank, and NantKwest
View HTML
Toggle Summary ImmunityBio Study Shows Positive T Cell and Antibody Immune Responses to its COVID-19 Vaccine Candidate that Targets Both Spike and Nucleocapsid Virus Proteins
Preclinical results show this next generation Adeno (hAd5) vaccine, which targets both spike (S) and nucleocapsid (N) SARS-CoV-2 proteins, generates CD4+ and CD8+ T-cell responses, both of which can form long-term immune memory.  Inclusion of nucleocapsid in this vaccine construct potentially
View HTML
Toggle Summary Engineered Killer Immune Cells Target Tumours and Their Immunosuppressive Allies View HTML
Toggle Summary NantKwest Announces Closing of $90.7 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
EL SEGUNDO, Calif. --(BUSINESS WIRE)--Jun. 29, 2020-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, announced today the closing of its previously announced underwritten public offering of an aggregate of 8,521,500 shares of its common stock
View HTML

Data Provided by Refinitiv. Minimum 15 minutes delayed.